Results 81 to 90 of about 6,317 (201)

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Journal of Asthma and Allergy, 2018
Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and ...
Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M   +6 more
doaj  

Identifying Therapeutic Targets for Bronchial Asthma: Systematic Druggable Genome‐Wide Mendelian Randomization

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background The treatment and prevention of bronchial asthma continue to present significant challenges. Mendelian randomization (MR) has been extensively employed to identify novel therapeutic targets. Consequently, we conducted a systematic MR analysis across the druggable genome to identify potential therapeutic targets for asthma.
Haijiao Wang, Peng Zhang, Hongpeng Yu, Li Shi, Tan Wang   +4 more
wiley   +1 more source

Bronchial thermoplasty: implementing best practice in the era of cost containment. [PDF]

, 2017
Increasing dependence on advanced technologies in the 21st century has created a dilemma between the practice and business of medicine. From information technology to robotic surgery, new technologies have expanded treatment possibilities and have ...
Kenyon, Nicholas, Louie, Samuel, Tan, Laren D, Yoneda, Ken Y   +3 more
core  

Molecular IgE Sensitization Profiling With Micro‐Arrayed Allergen Molecules in Adult Patients With Asthma From the LEAD Cohort: A Precision Medicine Approach

Allergy, Volume 81, Issue 1, Page 130-144, January 2026.
In the LEAD cohort, micro‐arrayed asthma allergens identified IgE‐sensitized adult asthma patients. Compared to non‐IgE‐sensitized patients, they had better lung function, took less ICS and had lower eosinophils. IgE‐sensitized patients were sensitized to a handful of respiratory allergen sources and may benefit from allergen‐specific forms of ...
Huey‐Jy Huang, Robab Breyer‐Kohansal, Katarzyna Niespodziana, Charmaine J. M. Lim, Marie‐Kathrin Breyer, Rudolf Valenta, Sylvia Hartl, the Allergochip Working Group, Maria‐Roxana Buzan, Kuan‐Wei Chen, Monica Daniela Cotarcă, Alexandra Dubovets, Pia Gattinger, Alexander Karaulov, Evgenii Kozlov, Carmen Panaitescu, Daria Trifonova, Mikhail Tulaev, Susanne Vrtala, Milena Weber, Lauriana‐Eunice Zbîrcea   +20 more
wiley   +1 more source

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan

Scientific Reports
Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma.
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko   +16 more
doaj   +1 more source

Effectiveness and Safety of Omalizumab for Chronic Spontaneous Urticaria During Pregnancy: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Michael Makris, Alexander Stratigos, Stamatios Gregoriou   +3 more
wiley   +1 more source

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results

Journal of Asthma and Allergy, 2019
Gary T Ferguson,1 Jeremy Cole,2 Magnus Aurivillius,3 Paul Roussel,4 Peter Barker,4 Ubaldo J Martin4 On behalf of the GRECO study investigators1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2OK Clinical Research, LLC,
Ferguson GT, Cole J, Aurivillius M, Roussel P, Barker P, Martin UJ   +5 more
doaj  

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study [PDF]

Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Bagnasco D., Beghe B., Blasi F., Bondi B., Braido F., Cameli P., Caminati M., Canonica G. W., Caruso C., Crimi C., El Masri Y., Giordani J., Guarnieri G., Latorre M., Mastrototaro A., Maule M., Menzella F., Micheletto C., Paggiaro P., Pini A., Pini L., Piras S., Senna G., Spanevello A., Vianello A., Visca D., Zappa M.   +26 more
core   +2 more sources

Targeting eosinophils: severe asthma and beyond [PDF]

, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma ...
Caminati, Marco, Guidolin, Lucia, Menzella, Francesco, Senna, Gianenrico   +3 more
core   +1 more source

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj